Business Context and Reporting Period
Company: Altria Group, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Altria is a leading U.S. tobacco company with a portfolio of smokeable products (cigarettes, cigars), oral tobacco products (moist smokeless tobacco, nicotine pouches), and e-vapor products. The company's vision is to transition adult smokers to smoke-free alternatives. Key subsidiaries include Philip Morris USA (PM USA), U.S. Smokeless Tobacco Company (USSTC), Helix Innovations, and NJOY. The company also holds equity investments in Anheuser-Busch InBev (ABI) and Cronos Group Inc.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Net Revenues | $24.0 billion | $24.5 billion | (1.9%) |
| Operating Income | $11.2 billion | $11.5 billion | (2.7%) |
| Net Earnings | $11.3 billion | $8.1 billion | +38.5% |
| Diluted EPS | $6.54 | $4.57 | +43.1% |
| Adjusted Net Earnings | $8.8 billion | $8.8 billion | 0% |
| Adjusted Diluted EPS | $5.12 | $4.95 | +3.4% |
| Operating Cash Flow | $8.8 billion | $9.3 billion | (5.7%) |
| Total Debt | $24.9 billion | $26.2 billion | (5.0%) |
| Cash and Equivalents | $3.1 billion | $3.7 billion | (16.2%) |
| Debt-to-Consolidated EBITDA | 2.1x | N/A | N/A |
Note: Reported Net Earnings and EPS were significantly boosted by a $2.7 billion pre-tax gain from the sale of IQOS System commercialization rights and favorable tax items. Adjusted metrics exclude these special items to reflect underlying operational performance.
Material Changes vs. Prior Period
- Volume Declines: Cigarette shipment volume decreased 10.2% to 68.6 billion units, driven by industry-wide declines, illicit trade, and consumer down-trading. Oral tobacco volume decreased 1.0%.
- Strategic Transactions:
- IQOS Sale: Assigned exclusive U.S. commercialization rights to the IQOS System to Philip Morris International (PMI), recognizing a $2.7 billion pre-tax gain.
- ABI Transaction: Sold a portion of its ABI investment for approximately $2.4 billion in proceeds, used to fund share repurchases.
- NJOY Integration: Completed the acquisition of NJOY in 2023; in 2024, made $250 million in contingent payments following FDA marketing orders for menthol products.
- Asset Impairment: Recorded a $354 million non-cash impairment of the Skoal trademark due to declining moist smokeless tobacco (MST) volumes and competition from nicotine pouches.
- Shareholder Returns: Completed a $3.4 billion share repurchase program in 2024. Increased the quarterly dividend by 4.1% to $1.02 per share.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2028 Goals: Altria is reassessing its U.S. smoke-free portfolio goals due to the proliferation of illicit flavored disposable e-vapor products. The company anticipates providing updated goals once market clarity improves.
- Optimize & Accelerate Initiative: Announced in October 2024, this multi-phase initiative aims to centralize work and outsource transactional tasks, targeting at least $600 million in cumulative cost savings over five years. Initial pre-tax charges of $68 million were recorded in 2024.
- Dividend Policy: Maintains a progressive dividend goal targeting mid-single-digit annual growth through 2028.
Key Risks and Contingencies
- NJOY Litigation (Critical): The U.S. International Trade Commission (ITC) issued a final determination in January 2025 finding that NJOY ACE infringes on JUUL patents, imposing an exclusion order and cease-and-desist orders. The order is under a 60-day review by the U.S. Trade Representative. If not rejected, the ban takes effect March 31, 2025, potentially barring NJOY ACE sales and triggering goodwill impairment.
- Illicit Trade: Illicit flavored disposable e-vapor products now represent over 60% of the e-vapor category, negatively impacting legitimate pod-based sales and cigarette volumes.
- Regulatory Environment: Ongoing FDA reviews of PMTAs, potential nicotine reduction standards, and flavor bans pose significant uncertainty. The FDA's enforcement against illicit products remains a key concern.
- Asset Valuation: The company monitors the Skoal trademark and e-vapor reporting unit goodwill for potential future impairment if volume declines or discount rates worsen.
Investor Verification Checklist
- ITC Ruling Status: Verify the outcome of the U.S. Trade Representative's review of the ITC's ban on NJOY ACE (deadline March 31, 2025) and its potential impact on e-vapor revenue and goodwill impairment.
- Illicit Market Share: Monitor trends in illicit e-vapor product sales and the effectiveness of federal/state enforcement actions, as this directly impacts NJOY growth and cigarette volume.
- Smoke-Free Goals: Await updated 2028 smoke-free volume and revenue targets, as current goals are under reassessment.
- Cost Savings Execution: Track the progress of the "Optimize & Accelerate" initiative to ensure the projected $600 million in savings materializes without disrupting operations.
- ABI Investment: Review the performance of the remaining ABI investment and the impact of foreign exchange rates on equity earnings.